In the Thy22-Tau mouse model of AD, which accumulate increased levels of human tau as they age and are used to study tau aggregation, T cells were depleted with a daily injection of anti-CD3 depleting antibody from 4 to 9 months of age and compared to WT controls. Here, MAPT is linked to Alzheimer disease.